<DOC>
	<DOCNO>NCT00634920</DOCNO>
	<brief_summary>This study design evaluate early conversion everolimus cyclosporine de novo renal transplant recipient improve long-term renal function slow progression chronic allograft nephropathy</brief_summary>
	<brief_title>Evaluation Early Conversion Everolimus From Cyclosporine de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>First second single renal transplant decease live donor Exclusion criterion Recipient organs renal transplant Present malignancy ( within last 2 year ) excise basal cell squamous cell carcinoma skin Severe liver disease At time randomization 7 week transplantation In addition criterion follow must meet time randomization : Patients maintain triple immunosuppressive regime consist cyclosporine , Enteric coat mycophenolate , corticosteroid Patients complete first 7 week without experience rejection Graft loss Low hemoglobin value , low number white blood cell platelets High cholesterol value Proteinuria Wound heal problem Current severe major local systemic infection Renal insufficiency Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>De novo renal transplantation</keyword>
</DOC>